Guide to Challenging Cases in Relapsed/Refractory Multiple Myeloma: Improving Practice
Release Date: October 06, 2017
Expiration Date: October 06, 2018
Expected time to complete this activity as designed: 120 minutes
There are no fees for participating in or receiving credit for this online activity.
Relapsed/refractory multiple myeloma (RRMM) is one of the most challenging hematologic malignancies that oncology practitioners will treat. Often, patients with RRMM have significant comorbidities and multiple prior treatment failures, all of which complicate both therapeutic decisions and subsequent patient management.
In this activity, adapted from a live symposium held in conjunction with a clinical hematologic malignancies meeting in September 2017, a panel of internationally known experts in myeloma discuss new and emerging therapeutic strategies for RRMM. Participants will gain a greater understanding of how to effectively address the real-world challenges of disease progression, comorbid conditions, high-risk factors, and treatment-emergent adverse events in their patients with RRMM.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in relapsed/refractory multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Identify management strategies for RRMM patients with comorbid conditions which will support delayed disease progression and improved outcomes
- Utilize pharmacotherapeutic strategies to mitigate or minimize the impact of treatment-emergent adverse events in a patient with RRMM
- Select from among available therapeutic options for RRMM to identify the most appropriate regimen for the individual patient with this disease
Introduction & Individualizing Treatment for Your Patients with RRMM: Selecting Among the Available Options – Robert Z. Orlowski, MD, PhD; Peter M. Voorhees, MD
Optimal Strategies for the Identification and Management of Treatment-Related Adverse Events – Ajay K. Nooka, MD, MPH, FACP
Improving Practice and Future Perspectives: Panel Discussion – All Faculty
Instructions for Participation and Credit
This activity is eligible for credit through October 6, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Robert Z. Orlowski, MD, PhD
Professor, Chair Ad Interim
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Robert Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University, St. Louis School of Medicine. Dr. Orlowski is a Professor and Chair Ad Interim in the Department of Lymphoma/Myeloma, and Professor in the Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Board-certified in internal medicine and medical oncology, Dr. Orlowski has published numerous book chapters, articles, and abstracts on cancer therapy with a focus on the pathogenesis of oncologic disease and mechanisms of action of chemotherapeutics. In addition, he is a reviewer for several journals, including Blood, Cancer Research, Journal of Clinical Oncology, and The New England Journal of Medicine. His clinical research efforts focus on novel clinical trials for patients with hematologic malignancies.
Ajay K. Nooka, MD, MPH, FACP
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Dr. Ajay Nooka earned his medical degree from Andhra Medical College in India before relocating to the United States. He received a master’s in public health from The University of Texas School of Public Health in Houston, Texas, and then completed his internship and residency at the Northeastern Ohio University College of Medicine, Ohio. He also pursued a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia. Dr. Nooka is an Assistant Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, Atlanta.
Dr. Nooka has a clinical interest in myeloma and bone marrow transplant. His research interests mainly involve improving novel therapeutic strategies for plasma cell dyscrasias and improving outcomes of myeloma patients. He has published several peer-reviewed articles in journals such as The New England Journal of Medicine, Lancet Oncology, Leukemia, Blood, Oncology, and Cancer. In addition, he currently serves as a reviewer for a number of journals including Lancet Oncology, Cancer, Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation.
Peter M. Voorhees, MD
Director, Outreach for Hematologic Malignancies
Plasma Cells Disorder Program
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute
Carolinas HealthCare System
Charlotte, North Carolina
Dr. Peter Voorhees received his medical degree from the University of Michigan. He continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Dr. Voorhees is Director of Outreach for Hematologic Malignancies, Plasma Cells Disorder Program, Department of Hematologic Oncology and Blood Disorders at Levine Cancer Institute, Charlotte, North Carolina. He was previously an assistant professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill.
Dr. Voorhees is board certified in hematology and internal medicine. His research focuses on the development of novel therapeutic strategies for the treatment of multiple myeloma. He is also interested in the basis of chemotherapy-related toxicity and the development of tools that predict for adverse events with treatment.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 2.0 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-167-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.0 contact hours. Program Number: 17-167-065
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Robert Orlowski has received honoraria related to formal advisory activities from Acetylon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Forma Therapeutics, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., an Amgen subsidiary, and Takeda Oncology. He has received grant support related to research activities from BioTheryX, Inc., Bristol-Myers Squibb, Celgene, Takeda Oncology, Onyx, and Spectrum Pharmaceuticals, Inc.
Dr. Ajay Nooka has received honoraria as a consultant from Adaptive Biotechnologies, Novartis AG, Onyx, and Spectrum Pharmaceuticals, Inc.
Dr. Peter Voorhees has received honoraria related to speakers’ bureau activities from Amgen Inc., Celgene Corporation, and Janssen Pharmaceuticals, Inc., as well as consultant fees from Celgene, Janssen, Novartis AG, and Takeda Oncology.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen and Celgene Corporation.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.